Viatris’ Legal Chief Holds Ground as Stock Buzz Surges, While Commercial Officer’s Sale Sparks Investor Speculation
Viatris insider confidence: CEO’s 25‑share hold amid 92% buzz, neutral sentiment, and a negative P/E signals long‑term belief in specialty drug growth.
3 minutes to read